DALTON, KING,LORIN A. THOMPSON, III,JIANLIANG, SHI,SRINIVASAN, THANGATHIRUPATHY,,JAYAKUMAR SANKARA, WARRIER,IMADUL, ISLAM,JOHN E., MACOR
申请号：
TR201815579
公开号：
TR201815579T4
申请日:
2015.01.06
申请国别(地区):
TR
年份:
2018
代理人:
摘要：
Refers to bicyclic Heterocyclic Derivatives of formula I, where the dotted line is a simple link or double； X is C (or C, N or o), where C and N can be replaced； L1 is a direct link or a player selected (- NH -, or - or u2013nhs NHC) 2 - (or)； L2 is a player selected (OR - C (S) -, 2 -, OR)Among other monociclico； CY1 is a Ring of 5 - 6 1 - 4 members containing heteroatoms selected from N, NH, or - C (o) -； monociclico Cy2 is a Ring of 4 - 12 members containing heteroatoms selected from 0 - 3 n, NH, o or s； r1 is Hydrogen, alkyl among others； R2 and R3 is Hydrogen, alkyd ILO or together form an oxo Group； R4 is Hydrogen, alkyl； n is 1 or 2.Preferred compounds are: 4 - (4-chlorobenzyl) - 7 - (3,5 - dimetilisoxazol - 4-yl) - 6 - methoxy - 3,4-dihydro - 2H - benzo [b] [1,4] oxazine, 6 - (3,5 - dimetilisoxazol - 4-yl) - 7 - methoxy - ((1 - 5 - metoxipiridin - 2 - yl) methyl) quinolin-2 (1H) ona； among others. It also relates to a Pharmaceutical Composition and a method of treatment.These compounds are inhibitors of bromodomain (BRD) and are useful in the treatment of autoimmune diseases, inflammatory and cancerTarifname genel olarak, tuzları dahil formül I'in bileşiklerinin yanı sıra bileşimler ve bileşikleri kullanmanın yöntemleri ile ilgilidir. Bileşikler, NR2B NMDA reseptörünün ligandlarıdır ve merkezi sinir sisteminin çeşitli hastalıklarının tedavisine yönelik kullanışlı olabilirler.
